Literature DB >> 16808549

Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.

Torbjörn Callréus1.   

Abstract

In the process of conceiving a pharmacovigilance plan, as proposed in the International Conference on Harmonisation E2E guideline, the challenge will be how to address possible safety issues with a set of appropriate pharmacovigilance methods. For successful planning, the various and sometimes complex dimensions of the adverse drug reaction in question have to be appropriately described. In order to accommodate these better, a 3-dimensional approach, based on dose, time and patient susceptibility, has recently been proposed (the DoTS model). This approach offers a way of presenting the various dimensions of the problem graphically. The aim of this article is to propose how an extended DoTS model, applied to three different scenarios, could give a better understanding of adverse drug reactions and assist in preparing a pharmacovigilance plan.

Entities:  

Mesh:

Year:  2006        PMID: 16808549     DOI: 10.2165/00002018-200629070-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  22 in total

Review 1.  Joining the DoTS: new approach to classifying adverse drug reactions.

Authors:  J K Aronson; R E Ferner
Journal:  BMJ       Date:  2003-11-22

2.  Approaches to combat with confounding by indication in observational studies of intended drug effects.

Authors:  Alex D McMahon
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Oct-Nov       Impact factor: 2.890

3.  Looking to the 21st century: have we learned from our mistakes, or are we doomed to compound them?

Authors:  Samuel Shapiro
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-04       Impact factor: 2.890

Review 4.  Principles of signal detection in pharmacovigilance.

Authors:  R H Meyboom; A C Egberts; I R Edwards; Y A Hekster; F H de Koning; F W Gribnau
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

Review 5.  Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects.

Authors:  A Cave; P Arlett; E Lee
Journal:  Pharmacol Ther       Date:  1999-09       Impact factor: 12.310

6.  Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.

Authors:  A Mattiasson; P Abrams; P Van Kerrebroeck; S Walter; J Weiss
Journal:  BJU Int       Date:  2002-06       Impact factor: 5.588

Review 7.  Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors?

Authors:  Julia Thumfart; Charles-Christoph Roehr; Klaus Kapelari; Uwe Querfeld; Paul Eggert; Dominik Müller
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

Review 8.  Drug-induced hepatotoxicity: 2005.

Authors:  Willis C Maddrey
Journal:  J Clin Gastroenterol       Date:  2005-04       Impact factor: 3.062

Review 9.  Soft steroids: a new approach to the treatment of inflammatory airways diseases.

Authors:  Maria G Belvisi; David J Hele
Journal:  Pulm Pharmacol Ther       Date:  2003       Impact factor: 3.410

10.  Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women.

Authors:  Gunnar Lose; Othon Lalos; Robert M Freeman; Philip van Kerrebroeck
Journal:  Am J Obstet Gynecol       Date:  2003-10       Impact factor: 8.661

View more
  3 in total

1.  EIDOS: a mechanistic classification of adverse drug effects.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

2.  The development of a scoring and ranking strategy for a patient-tailored adverse drug reaction prediction in polypharmacy.

Authors:  Andrei Valeanu; Cristian Damian; Cristina Daniela Marineci; Simona Negres
Journal:  Sci Rep       Date:  2020-06-12       Impact factor: 4.379

Review 3.  Risk undermined in the bilateral pharmaceutical regulatory system in Taiwan.

Authors:  Hui-Po Wang; Chun-Li Wang
Journal:  J Food Drug Anal       Date:  2018-01-17       Impact factor: 6.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.